Create Account Sign In Contact Us Stay up to Date: Mail Facebook Twitter RSS
Explore Science for the Benefit of:
fighting cancer
advancing technology
enriching education
protecting our planet
improving health & medicine
exploring the physical world
What’s your wish for a better tomorrow?
make a dedication
A group of high-school students in the Bronx uses the interactive website Proteopedia—developed by Prof. Joel Sussman and colleagues at Weizmann—to investigate proteins and other biological macromolecules, with real scientific results.
From:
Pioneering discoveries by Weizmann scientists and colleagues may result in improved understanding of why prolonged, repeated exposure to stress can lead to anxiety disorders and depression.
February 22, 2012
Understanding the details of ovulation is key to developing fertility treatments. Now, after baffling scientists for decades, a major mystery concerning an early step in the ovulation process has been solved.
From: Haaretz
Prof. David Milstein won for his innovative research on new ways to create compounds using materials containing metals. His work could lead to cleaner industrial processes—and a cleaner environment.
A Weizmann team's findings on how cells adhere to surfaces may be relevant to the cells lining blood vessels, and could help identify therapeutic targets for problems such as arterial plaque formation.
February 16, 2012
The Weizmann Institute and the Max Planck Society have launched a center to study humankind’s history in new ways, such as by using sophisticated technologies borrowed from physics.
January 11, 2012
Dr. Gad Asher investigates the function and role of our internal biological clocks. His work could shed light on conditions ranging from jetlag and sleep disturbances to cancer, diabetes, obesity, and aging.
January 01, 2012
Prof. Irit Sagi has successfully tricked the immune system into targeting an enzyme involved in the autoimmune process. Her synthetic molecules could lead to new treatments for Crohn’s and other autoimmune diseases.
December 26, 2011
From: Bloomberg Business Week
Teva Pharmaceutical Industries Ltd., the world’s largest generic-drug maker, is seeking to transform a compound once rejected by Sanofi into the first treatment to succeed insulin for Type 1 diabetes.
December 20, 2011
The American Committee appoints Eleanore Levy as its first Director of Personalized Philanthropy. Levy will help donors maximize their philanthropic impact, while advancing the Institute’s goals.
December 19, 2011